

Our ref: FOI ID 34152

23 February 2017

southseftonccg.foi@nhs.net

NHS South Sefton CCG

Merton House

Stanley Road

Bootle

Merseyside

L20 3DL

Tel: 0151 247 7000

Re: Freedom of Information Request

Please find below the response to your recent Freedom of Information request regarding medicines which are marketed for the treatment of chronic obstructive pulmonary disease within NHS South Sefton CCG.

Request/[Response](#):

We request information in relation to all the medicines listed below which are marketed for the treatment of chronic obstructive pulmonary disease:

- a) Anoro (vilanterol and umeclidinium) which is marketed by GlaxoSmithKline
- b) Braltus (tiotropium) which is marketed by Teva
- c) Duaklir (aclidinium bromide and formoterol fumarate dihydrate) which is marketed by Astra Zeneca
- d) Eklira (aclidinium) which is marketed by Astra Zeneca
- e) Incruse (umeclidinium) which is marketed by GlaxoSmithKline
- f) Seebri (glycopyrronium) which is marketed by Novartis
- g) Spiolto (tiotropium and olodaterol) which is marketed by Boehringer Ingelheim
- h) Spiriva (tiotropium) which is marketed by Boehringer Ingelheim
- i) Ultibro (indacaterol and glycopyrronium) which is marketed by Novartis or Pfizer

Chair: Dr Andrew Mimmagh
Chief Officer: Fiona Taylor

(the “**COPD Medicines**”).

In respect of each of the COPD Medicines, please could you provide us with the following information:

- 1) A copy of any agreement relating to a rebate, discount, patient access, risk-sharing or other pricing scheme entered into by NHS South Sefton CCG in relation to the COPD Medicines which results in NHS South Sefton CCG paying less than the NHS list price for such COPD Medicines (whether by way of discount, rebate etc).

NHS South Sefton CCG currently does not have any rebate schemes in place in South Sefton for any of the listed COPD medicines.

- 2) A copy of any communications between NHS South Sefton CCG and the company or companies marketing such COPD Medicine in relation to such scheme

Not applicable

- 3) Any information or requests sent to GP practices comprised within the CCG in the 6 months since contract signature with respect to such COPD Medicines schemes

Not applicable